Coldstream Capital Management’s Halozyme HALO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$676K Sell
8,635
-228
-3% -$15.5K 0.01% 618
2026
Q1
$573K Sell
8,863
-8
-0.1% -$564 0.01% 673
2025
Q4
$597K Sell
8,871
-43
-0.5% -$2.89K 0.01% 646
2025
Q3
$654K Buy
8,914
+165
+2% +$11K 0.01% 622
2025
Q2
$455K Sell
8,749
-425
-5% -$24.2K 0.01% 700
2025
Q1
$585K Buy
9,174
+121
+1% +$7.03K 0.01% 543
2024
Q4
$433K Sell
9,053
-198
-2% -$10.2K 0.01% 666
2024
Q3
$534K Buy
9,251
+2,384
+35% +$137K 0.01% 589
2024
Q2
$360K Buy
6,867
+124
+2% +$5.44K 0.01% 693
2024
Q1
$274K Sell
6,743
-178
-3% -$6.67K 0.01% 802
2023
Q4
$256K Buy
+6,921
New +$261K 0.01% 773
2023
Q1
– Sell
-4,930
Closed -$281K – 846
2022
Q4
$281K Buy
+4,930
New +$252K 0.01% 631
2022
Q2
$200K Buy
+4,562
New +$197K 0.01% 735

Other funds holding HALO

Coldstream Capital Management's HALO Position: Q2 2026 in Review

Coldstream Capital Management reduced its Halozyme (HALO) stake by 2.6% in Q2 2026, selling an estimated $15.5K and leaving 8,635 shares worth $676K. The position accounts for 0.01% of the portfolio, ranked #618.

Coldstream Capital Management first reported a position in HALO in Q2 2022 and has held it in 13 quarters since. 674 funds tracked by Wall St. Rank hold HALO as of Q2 2026.

  • Coldstream Capital Management held 8,635 shares of Halozyme worth $676K as of Q2 2026.
  • Coldstream Capital Management sold 228 Halozyme shares in Q2 2026, an estimated $15.5K.
  • Halozyme made up 0.01% of Coldstream Capital Management's portfolio in Q2 2026, its #618 holding.
  • Coldstream Capital Management first reported a position in Halozyme in Q2 2022 and has held it in 13 quarters since.
  • 674 funds tracked by Wall St. Rank held Halozyme as of Q2 2026.

Based on Coldstream Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.